France's Dyameo raises €3M to bring real-time cancer-margin tool to market
What's the deal? French medtech DyameoDealroom has a profile for this one. Try Dealroom → has raised €3 million to commercialise TempoTouch, a system that helps surgeons check in real time whether they have fully removed a tumour. Returning investors Medevice Capital and NACODealroom has a profile for this one. Try Dealroom → were joined by Bpifrance Amorçage IndustrielDealroom has a profile for this one. Try Dealroom →, OBRATORIDealroom has a profile for this one. Try Dealroom → and Estellior Capital, alongside unnamed French entrepreneurs.
What's the endgame? TempoTouch tackles a question surgeons face at every tumour removal: are the edges of the excised tissue — the resection margins — free of cancer cells? If cells remain, patients may need further treatment or another operation.
The system uses patented reagent capsules that clip onto a probe linked to an optical fibre; a TempoTouch unit reads the signal and displays results during surgery. The technology originated in two University of Limoges laboratories, with lung, head and neck, and skin cancers as early targets.
Why now? Dyameo, a seven-person company based in Limoges, has completed a first clinical trial across six French surgical centres, industrialised its manufacturing and filed patents. "This round marks our shift from innovation to commercial launch," said co-founder and president Cédric Enguehard (translated from French).
What's the money for? The €3 million will fund higher production of the device and its capsules, build a sales team and target cancer-surgery centres in France and abroad, according to Bpifrance. The company is targeting CE marking and a commercial launch in 2026.
What could go wrong? The company has not published trial results showing improved patient outcomes, and the device is not yet approved for routine use. Commercial deployment depends on securing CE marking, and adoption will hinge on clinical evidence and how the tool fits into operating-room workflows.
The signal: European medtech funding has concentrated in larger rounds — Oxford's OMass Therapeutics raised $310 million the same month. Dyameo's modest raise matters less for its size than for moving a clinical-stage cancer-surgery device toward market, where its fate will rest on regulators and surgeons.
Read more: born2invest.com
Image credit: Generated with Gemini
